Polymedication in sodium warfarin users of the Public Health System and associated variables

• Autor(a) principal: Kleibert, Karine Raquel Uhdich
• Data de Publicação: 2020
• Outros Autores: Hermann, Emelli Fin, Nunes, Paula Lorenzoni, Schneider, Aline, Stumm, Eniva Miladi Fernandes, Colet, Christiane de Fátima
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Ciências em Saúde
• Texto Completo: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/900
• topic: Drug-related side effects and adverse reactions; Warfarin; Drug interactions; Varfarina; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Interações medicamentosas.

Objective: To verify the use of polymedication in warfarin users and its association with clinical variables. Methods: cross-sectional study, with warfarin users, of both sexes. For data collection, a structured questionnaire was used, with open and closed questions, on socioeconomic, clinical data and aspects related to pharmacotherapy (adverse reactions, drug interactions, systemic blood pressure indexes, fasting glucose values, self-medication practice, overweight, bleeding episodes and thromboembolism). Results: the average age of the participants was 69.1 ± 13.6 years, mostly female (64.6%), married (43.8%), and white (85.4%). As for education, 41.7% attended incomplete elementary school. Polymedicated patients totaled 89.6%, and patients using ten or more medications, 31.3%. The average number of medications per patient was 8.2 ± 3.5. There was an association between polymedication, occurrence of adverse reactions (94.7% vs 5.3%; p = 0.042) and the number of potential drug interactions, total (8.9 ± 5.0 vs 1.2 ± 1.6; p = 0.001) and severe (3.1 ± 2.4 vs 0.4 ± 0.6; p = 0.017). The other variables studied were not associated with polymedication. Conclusion: the results showed negative interference from polymedication in the occurrence of adverse reactions, and in the potential total and serious drug interactions. There is a need to know the impact of these variables on the polymedicated anticoagulated patient to plan risk reduction strategies and to optimize benefits.